Last reviewed · How we verify
teriparatide and alendronate
This combination pairs teriparatide (a PTH analog that stimulates bone formation) with alendronate (a bisphosphonate that inhibits bone resorption) to address osteoporosis through complementary anabolic and anti-catabolic pathways.
This combination pairs teriparatide (a PTH analog that stimulates bone formation) with alendronate (a bisphosphonate that inhibits bone resorption) to address osteoporosis through complementary anabolic and anti-catabolic pathways. Used for Osteoporosis in postmenopausal women and men at high risk of fracture.
At a glance
| Generic name | teriparatide and alendronate |
|---|---|
| Also known as | Forteo, Fosamax |
| Sponsor | Medical University of Vienna |
| Drug class | Combination therapy: PTH analog + bisphosphonate |
| Target | PTH1 receptor (teriparatide); farnesyl pyrophosphate synthase (alendronate) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Teriparatide activates PTH1 receptors on osteoblasts to increase bone formation and mineral density. Alendronate inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Together, they aim to maximize net bone gain in osteoporosis patients, though sequential rather than concurrent dosing is typically recommended to avoid antagonism.
Approved indications
- Osteoporosis in postmenopausal women and men at high risk of fracture
Common side effects
- Nausea
- Arthralgia
- Headache
- Dizziness
- Gastrointestinal upset (alendronate component)
Key clinical trials
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk (PHASE3)
- Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover (PHASE4)
- Precision Medicine Approach for Osteoporosis - Follow Up Study (PHASE4)
- Post-fracture Medication and Mortality
- Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide (PHASE2)
- Renal Osteodystrophy: An Individual Management Approach (NA)
- Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- teriparatide and alendronate CI brief — competitive landscape report
- teriparatide and alendronate updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI